Type 4 diabetes is a proposed form of diabetes driven by aging rather than obesity. The term comes from research at the Salk Institute, where scientists discovered that insulin resistance in older, lean mice has a completely different cellular cause than the insulin resistance seen in type 2 diabetes. It is not yet an official clinical diagnosis, but the concept helps explain why some older adults develop blood sugar problems despite maintaining a healthy weight.
How Type 4 Differs From Type 2
Type 2 diabetes is strongly linked to excess body fat. When someone carries too much weight, their fat tissue becomes inflamed in a specific way that makes cells less responsive to insulin. Type 4 diabetes, by contrast, appears to affect people who are lean and aging. The underlying biology is essentially the opposite of what happens in type 2.
In the Salk Institute research, mice with type 2 diabetes had abnormally low levels of certain immune cells called regulatory T cells (Tregs) in their fat tissue, paired with large amounts of fat. Mice with type 4 diabetes showed the reverse pattern: they had little excess fat but abnormally high levels of these same immune cells accumulating in their fat tissue. This buildup of Tregs progressively increases with age, not with weight gain, and it directly interferes with how fat tissue responds to insulin.
This distinction matters because treatments that work for one type don’t necessarily work for the other. In the Salk experiments, blocking the accumulation of Tregs in fat tissue reversed the age-related insulin resistance. But that same approach did nothing to prevent type 2 insulin resistance. The two conditions share an end result (high blood sugar) but arrive there through fundamentally different immune pathways.
The Immune System’s Role in Aging and Blood Sugar
Your immune system doesn’t just fight infections. Immune cells live throughout your body, including inside fat tissue, where they help regulate metabolism. Regulatory T cells are normally beneficial. They calm inflammation and keep the immune system in check. But as you age, these cells progressively accumulate in fat tissue in ways that actually suppress the tissue’s ability to respond to insulin.
Think of it this way: in type 2 diabetes, fat tissue is too inflamed. In type 4, the problem is almost too much immune regulation in the wrong place. The Tregs crowd into fat tissue and, paradoxically, make it less metabolically functional. Research published through the Salk Institute’s labs established that mice genetically unable to accumulate these fat-resident Tregs were protected against age-related insulin resistance, yet remained fully susceptible to obesity-driven insulin resistance. That’s strong evidence these are two genuinely separate diseases sharing similar symptoms.
Separate research from the American Diabetes Association has also identified another piece of the aging puzzle. An enzyme that ramps up in inflammatory cells with age produces excess nitric oxide, which chemically modifies proteins in a way that blocks insulin signaling. In animal studies, eliminating this enzyme, inhibiting it with drugs, or even reducing it through exercise all protected against this form of insulin resistance.
Symptoms and Detection
Type 4 diabetes doesn’t have its own unique symptom profile. The signs mirror what you’d expect from any form of insulin resistance or elevated blood sugar: fatigue, increased thirst, frequent urination, increased hunger, and blurred vision. The catch is that early insulin resistance often produces no symptoms at all. As long as the pancreas can compensate by producing extra insulin, blood sugar stays in a normal range and the problem remains invisible.
This is especially tricky for lean, older adults. Because they don’t fit the typical profile for type 2 diabetes (overweight, sedentary), their insulin resistance may go unnoticed longer. Standard screening tools like fasting glucose tests, A1c tests, and lipid panels can detect elevated blood sugar and metabolic changes, but they won’t distinguish between type 2 and type 4 as a cause. There is currently no routine clinical test that specifically identifies the Treg-driven mechanism behind type 4.
Why This Classification Matters
You may have also seen references to “type 3 diabetes,” an informal term sometimes used to describe the insulin resistance found in brain tissue of people with Alzheimer’s disease. Neither type 3 nor type 4 is recognized as an official diagnosis by major diabetes organizations. The standard clinical categories remain type 1, type 2, and gestational diabetes.
Still, the type 4 concept carries real practical weight. Roughly 20% of people diagnosed with type 2 diabetes are not overweight, and many of them are older. For these patients, the standard advice to lose weight doesn’t make much sense, and medications designed around obesity-driven insulin resistance may not target the actual problem. If the Treg-driven mechanism identified in mice also operates in humans, it could eventually lead to immune-targeted therapies designed specifically for lean, older patients with blood sugar problems.
For now, the research remains primarily in animal models. But the core finding, that aging and obesity drive insulin resistance through opposite immune mechanisms in fat tissue, has shifted how researchers think about diabetes as a single disease versus a family of related but distinct conditions. It validates what many older, lean patients already suspect: that their blood sugar issues don’t fit neatly into the type 2 box.